glp 1 pharmaceutical companies GLP-1 Analogues Transform Metabolic Disease Management | Universal Healthcare posted on the topic Refills Launches Clinician-Led GLP-1 &

A., Elahi, D., Shen, Y

Metformin use is associated with slowed cognitive decline and reduced incident dementia in older adults with type 2 diabetes: the Sydney Memory and Ageing Study

Otherwise, it won't produce noticeable results and will only serve as an additional, rather than a key, part of a weight loss program

Tumor microenvironment remodeling and tumor therapy based on M2-like tumor associated macrophage-targeting nano-complexes

The primary aim of the present trial was to compare the effects of liraglutide 1.8 and 3.0 mg, the maximum approved dose in treatment of type 2 diabetes and the intended clinical dose in weight management, respectively, on gastric emptying in obese individuals without T2DM, with the focus on demonstrating equivalence between the two doses over a 5-h period, in order to support that no dose adjustment of concomitantly administered oral medications would be required during treatment with liraglutide 3.0 mg